Despite many advances in pharmacotherapy over the past half centurye, only a fraction of
patients with Major Depressive Disorder (MDD) can achieve remission after the first or …

Despite the large number of depressed patients who do not respond to first-line
antidepressants, the evidence base of alternate strategies is quite thin. In this article, a …

Treatment-resistant depression (TRD) presents many challenges for both patients and
physicians. This review aims to evaluate the current status of the field of TRD and reflects the …

Major depressive disorder is a common and disabling illness that leads to significant
reductions in quality of life and considerable cost to society. Despite numerous advances in …

Because two-thirds of patients with Major Depressive Disorder do not achieve remission
with their first antidepressant, we designed a trial of three “next-step” strategies: switching to …

Major depressive disorder (MDD) is a common and serious illness of our times, associated
with monoamine deficiency in the brain. Moreover, increased levels of cortisol, possibly …

The array of drugs available for the treatment of Major Depressive Disorder (MDD) continues
to increase. Treatment emphasis has shifted away from an “adequate” response to an …

Background: The large majority of depressed patients fail to remit on the first antidepressant
prescribed. These patients with residual symptoms have higher relapse rates and poorer …

Treatment-resistant depressive disorders remain a significant problem in clinical practice in
spite of an increase in the number of antidepressive treatment options and the development …

Only 50% of depressed patients achieve remission of symptoms after 2 trials of
antidepressants. Therefore one half of patients are considered treatment resistant. Studies …